Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours

RETRACTED: Lysyl Oxidase-like 2 Deaminates Lysine 4 in Histone H3

(2012) Nicolás Herranz et al.   MOLECULAR CELL

Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging

(2011) Mukund Seshadri et al.   ANGIOGENESIS

Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane

(2011) M. Bignon et al.   BLOOD

LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution

(2011) H. E. Barker et al.   CANCER RESEARCH

Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas

(2011) Gema Moreno-Bueno et al.   EMBO Molecular Medicine

The Enzymatic Activity of Lysyl Oxidas-like-2 (LOXL2) Is Not Required for LOXL2-induced Inhibition of Keratinocyte Differentiation

(2011) Jennie Lugassy et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions

(2011) C-R Pradeep et al.   ONCOGENE

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

(2011) Shom Goel et al.   PHYSIOLOGICAL REVIEWS

Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation

(2011) C. C.-L. Wong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Modulation of Lysyl Oxidase-like 2 Enzymatic Activity by an Allosteric Antibody Inhibitor

(2010) Hector M. Rodriguez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

(2010) Vivian Barry-Hamilton et al.   NATURE MEDICINE

A novel asymmetric 3D in-vitro assay for the study of tumor cell invasion

(2009) Vera Brekhman et al.   BMC CANCER

Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic Niche

(2009) Janine T. Erler et al.   CANCER CELL

Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway

(2009) Liang Peng et al.   CARCINOGENESIS

Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling

(2009) Kandice R. Levental et al.   CELL

The Lysyl Oxidases LOX and LOXL2 Are Necessary and Sufficient to Repress E-cadherin in Hypoxia

(2009) Ruth Schietke et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Semaphorin-3B Is an Angiogenesis Inhibitor That Is Inactivated by Furin-Like Pro-Protein Convertases

(2008) A. Varshavsky et al.   CANCER RESEARCH

Lysyl Oxidase-Like 2 as a New Poor Prognosis Marker of Squamous Cell Carcinomas

(2008) H. Peinado et al.   CANCER RESEARCH

VE-statin/egfl7 regulates vascular elastogenesis by interacting with lysyl oxidases

(2008) Etienne Lelièvre et al.   EMBO JOURNAL

The tumor microenvironment and its contribution to tumor evolution toward metastasis

(2008) Girieca Lorusso et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Matrigel cytometry: A novel method for quantifying angiogenesis in vivo

(2008) A. Adini et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Successful Inhibition of Tumor Development by Specific Class-3 Semaphorins Is Associated with Expression of Appropriate Semaphorin Receptors by Tumor Cells

(2008) Boaz Kigel et al.   PLoS One